BRPI0923048A2 - "composto de aminopirazol". - Google Patents

"composto de aminopirazol".

Info

Publication number
BRPI0923048A2
BRPI0923048A2 BRPI0923048A BRPI0923048A BRPI0923048A2 BR PI0923048 A2 BRPI0923048 A2 BR PI0923048A2 BR PI0923048 A BRPI0923048 A BR PI0923048A BR PI0923048 A BRPI0923048 A BR PI0923048A BR PI0923048 A2 BRPI0923048 A2 BR PI0923048A2
Authority
BR
Brazil
Prior art keywords
aminopyrazole compound
aminopyrazole
compound
Prior art date
Application number
BRPI0923048A
Other languages
English (en)
Portuguese (pt)
Inventor
Ryan Clayton Joshua
Ma Liandong
Paul Burkholder Timothy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0923048(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0923048A2 publication Critical patent/BRPI0923048A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0923048A 2008-12-16 2009-12-08 "composto de aminopirazol". BRPI0923048A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16
PCT/US2009/067056 WO2010074947A1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Publications (1)

Publication Number Publication Date
BRPI0923048A2 true BRPI0923048A2 (pt) 2018-09-25

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923048A BRPI0923048A2 (pt) 2008-12-16 2009-12-08 "composto de aminopirazol".

Country Status (38)

Country Link
US (2) US7897600B2 (https=)
EP (1) EP2379557B1 (https=)
JP (1) JP5509217B2 (https=)
KR (1) KR101300458B1 (https=)
CN (1) CN102232075B (https=)
AR (1) AR074240A1 (https=)
AU (1) AU2009330503B2 (https=)
BR (1) BRPI0923048A2 (https=)
CA (1) CA2744714C (https=)
CL (1) CL2011001445A1 (https=)
CO (1) CO6331442A2 (https=)
CR (1) CR20110341A (https=)
CY (1) CY1113637T1 (https=)
DK (1) DK2379557T3 (https=)
DO (1) DOP2011000190A (https=)
EA (1) EA019554B1 (https=)
EC (1) ECSP11011132A (https=)
ES (1) ES2396617T3 (https=)
HN (1) HN2011001697A (https=)
HR (1) HRP20120918T1 (https=)
IL (1) IL213065A0 (https=)
JO (1) JO2833B1 (https=)
MA (1) MA32900B1 (https=)
MX (1) MX2011006441A (https=)
MY (1) MY158691A (https=)
NZ (1) NZ592641A (https=)
PA (1) PA8851101A1 (https=)
PE (1) PE20110549A1 (https=)
PL (1) PL2379557T3 (https=)
PT (1) PT2379557E (https=)
SG (1) SG172202A1 (https=)
SI (1) SI2379557T1 (https=)
SV (1) SV2011003949A (https=)
TN (1) TN2011000292A1 (https=)
TW (1) TWI440640B (https=)
UA (1) UA104743C2 (https=)
WO (1) WO2010074947A1 (https=)
ZA (1) ZA201103942B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
CN103458970A (zh) * 2011-03-07 2013-12-18 泰莱托恩基金会 Tfeb磷酸化抑制剂及其应用
US9573960B2 (en) * 2011-06-15 2017-02-21 Life & Brain Gmbh Glioblastoma inhibiting compounds and their use
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
AR101504A1 (es) 2014-08-11 2016-12-21 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
TW201618775A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物
EP3541817B1 (en) * 2016-11-17 2020-12-23 Bristol-Myers Squibb Company Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
PL369856A1 (en) 2001-12-21 2005-05-02 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
ES2347172T3 (es) 2005-02-16 2010-10-26 Astrazeneca Ab Compuestos quimicos.
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
JP5054004B2 (ja) * 2005-07-01 2012-10-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としてのピリミジン置換ベンゾイミダゾール誘導体
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
CN101321759A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
JP5052518B2 (ja) * 2005-10-06 2012-10-17 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
KR20080080584A (ko) * 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
JP2010508315A (ja) * 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
JP2010524911A (ja) * 2007-04-18 2010-07-22 アストラゼネカ アクチボラグ ５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用
JP2010527999A (ja) 2007-05-23 2010-08-19 フアーマコペイア・エル・エル・シー ＰＫＣ−θ阻害剤としてのプリノン類および１Ｈ−イミダゾピリジノン類
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Also Published As

Publication number Publication date
HRP20120918T1 (hr) 2012-12-31
CA2744714A1 (en) 2010-07-01
HK1160109A1 (en) 2012-08-10
MY158691A (en) 2016-10-31
UA104743C2 (ru) 2014-03-11
AU2009330503A1 (en) 2010-07-01
TWI440640B (zh) 2014-06-11
EP2379557B1 (en) 2012-10-31
ZA201103942B (en) 2012-08-29
JO2833B1 (en) 2014-09-15
US20100286139A1 (en) 2010-11-11
TW201024301A (en) 2010-07-01
WO2010074947A1 (en) 2010-07-01
KR20110084993A (ko) 2011-07-26
ES2396617T3 (es) 2013-02-22
KR101300458B1 (ko) 2013-08-30
EA201170831A1 (ru) 2011-12-30
PE20110549A1 (es) 2011-08-04
TN2011000292A1 (en) 2012-12-17
HN2011001697A (es) 2013-11-26
SI2379557T1 (sl) 2013-02-28
CO6331442A2 (es) 2011-10-20
US7897600B2 (en) 2011-03-01
SG172202A1 (en) 2011-07-28
AR074240A1 (es) 2011-01-05
JP5509217B2 (ja) 2014-06-04
MX2011006441A (es) 2011-07-19
CN102232075A (zh) 2011-11-02
JP2012512158A (ja) 2012-05-31
DK2379557T3 (da) 2012-12-17
US20100152181A1 (en) 2010-06-17
PL2379557T3 (pl) 2013-03-29
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
CL2011001445A1 (es) 2011-11-11
ECSP11011132A (es) 2011-07-29
EP2379557A1 (en) 2011-10-26
NZ592641A (en) 2013-01-25
IL213065A0 (en) 2011-07-31
CN102232075B (zh) 2013-12-11
DOP2011000190A (es) 2011-07-31
PA8851101A1 (es) 2010-07-27
CY1113637T1 (el) 2016-06-22
PT2379557E (pt) 2013-01-14
CA2744714C (en) 2013-06-25
CR20110341A (es) 2011-07-13
AU2009330503B2 (en) 2012-06-07
EA019554B1 (ru) 2014-04-30

Similar Documents

Publication Publication Date Title
BRPI0923048A2 (pt) "composto de aminopirazol".
BRPI0910229A2 (pt) Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
BRPI0815717A2 (pt) Compostos de imidazopirazina.
BRPI0922904A2 (pt) "compostos"
FR2909857B1 (fr) Endovalve.
BRPI0813235A2 (pt) Combinação anti-helmíntica.
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
BRPI0923047A2 (pt) "conjugados de proteínas-oligossacarídeos".
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
DE602007009284D1 (de) 3-aza-bicycloä3.1.0ühexanderivate
BRPI0918472A2 (pt) composto 2,4-diaminopirimidina
DK2205562T3 (da) 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
BRPI0813245A2 (pt) Escova de dentes.
BRPI0914533A2 (pt) "métodos"
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
BRPI0912716A2 (pt) composto.
FR2932490B1 (fr) Composition polyamide.
BRPI0916395A2 (pt) compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
DK2792662T3 (da) Morphinanforbindelser
DE112007003187A5 (de) Wegfahrsperre
EP2214719A4 (en) Metallofullerene-DYE
MA30860B1 (fr) Myrtillier denomme "c97-390"
BRPI0907749A2 (pt) Derivados de 3,8-diaminotetrahidroquinolina
FR2937254B1 (fr) Harnais d'antichute.
BRPI0818848A2 (pt) Compostos de 2,3-di-idro-benzofurano

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.